NCT00356096已完成4 期
A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 404
- 试验地点
- 69
- 主要终点
- The primary endpoint is the change from baseline after 12 weeks of treatment in: IRLS total score, IRLS item 10 score and BDI-II total score
研究概览
简要总结
The primary objective of this study is to determine the efficacy of pramipexole 0.125 mg to 0.75 mg daily versus placebo on RLS symptoms and on associated mood disturbances and depressive symptoms, after 12 weeks of treatment
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent consistent with ICH-GCP and local IRB/IEC requirements obtained prior to any study procedures being performed and the ability and willingness to comply with study treatment regimen and to attend study assessments.
- •Male or female out-patients aged 18-80 years.
- •Diagnosis of idiopathic RLS according to the clinical RLS criteria of the IRLSSG [P03-03355]. All four criteria must be present to fulfil the diagnosis of RLS:
- •An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. (Sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs) The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. (When symptoms are very severe, the worsening at night may not be noticeable but must have been previously present).
- •RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to baseline (Visit 2).
- •In addition all of the following must be demonstrated at Visit 2 (baseline):
- •IRLS total score >15 A score of >=2 for item 10 of the IRLS rating scale
排除标准
- •Women of child-bearing potential who do not use an adequate method of contraception
- •Any women of child-bearing potential not having negative pregnancy test at screening
- •Breastfeeding women
- •Concomitant or previous pharmacologic therapy for RLS
- •All treatment less than 14 days before baseline or concomitant treatment with medication or dietary supplements, which could significantly influence RLS symptoms
- •Withdrawal symptoms of any medication must not be present at baseline
- •Previous pramipexole non-responders in other indications than RLS.
- •Hypersensitivity to pramipexole or any other component of the investigational product
- •Diagnosis of diabetes mellitus requiring insulin
- •Any of the following laboratory results at screening: clinically significant abnormalities at the investigatos discretion; Hb below lower limit of normal
- •Clinically significant renal disease at screening
- •Clinically significant hepatic disease at screening
- •Serum ferritin <10 ng/mL at screening.
- •History of/or malignant melanoma.
- •History of/or clinically significant vision abnormalities
- •History of/or any other sleep disorder
- •History of/or major depressive disorder or any psychotic disorder, mental disorders or any present Axis I psychiatric disorder according to DSM IV requiring any medical therapy, or BDI-II total score >28
- •History of/or clinical signs of suicidal behaviour, suicide ideation or acute suicidal tendency according to the investigators opinion
- •History of/or alcohol abuse or drug addiction within the last 2 years before screening
- •Patients on a shift-work-schedule or otherwise unable to follow a regular sleep-wake cycle
- •Participation in an investigational drug study within one month prior to the start of this study
- •Patients with any clinically significant conditions that in the opinion of the investigator
结局指标
主要结局
The primary endpoint is the change from baseline after 12 weeks of treatment in: IRLS total score, IRLS item 10 score and BDI-II total score
时间窗: 12 weeks
次要结局
- The following endpoints will be analysed: CGI-I, IRLS and BDI-II responder rate, VAS score for pain in limbs, RLS-6 item scores, HADS-A score, RLS-QoL score, PGI responder rate, Adverse events profile, Systolic and diastolic blood pressure, Pulse rate(12 weeks)
研究者
研究点 (69)
Loading locations...
相似试验
已完成
3 期
Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's DiseaseParkinson DiseaseNCT00240409Boehringer Ingelheim208
已完成
3 期
Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) PatientsRestless Legs SyndromeNCT00275457Boehringer Ingelheim346
已完成
3 期
Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)Restless Legs SyndromeNCT00654498Boehringer Ingelheim306
已完成
4 期
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) PatientsParkinson DiseaseNCT00402233Boehringer Ingelheim312
终止
4 期
Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis PatientsRestless Legs SyndromeNCT03817554Dong Jie21